• The diagnosis of myasthenia gravis was made in 165 patients whose symptoms were either aggravated by one-tenth of the minimal curarizing dose of tubocurarine chloride or objectively improved by intravenously administered neostigmine. Most patients satisfied both criteria. Mestinon was compared with neostigmine in these patients. Mestinon was effective in controlling the myasthenic symptoms, particularly the dysphagia. Its action was smoother because more prolonged, and no distressing sideeffects were observed even in patients who used it as long as 17 months.
Tether JE. TREATMENT OF MYASTHENIA GRAVIS WITH MESTINON BROMIDE. JAMA. 1956;160(3):156–158. doi:10.1001/jama.1956.02960380004002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: